Better way to image metastatic prostate cancer

January 27, 2016

Conventional imaging methods have limited sensitivity for detecting metastatic prostate cancer. With appropriate, timely treatment vital to survival and quality of life, better imaging has been an ongoing goal.

A recent study, reported in the January issue of The Journal of Nuclear Medicine, has now shown in a prospective, systematic manner that a PET/CT scan, using the radiotracer F-18-DCFBC to target prostate-specific membrane antigen (PSMA), is significantly more effective than other detection methods currently in use.

Read the full article.